# Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT

> **NCT07037680** · PHASE2 · RECRUITING · sponsor: **JIANYANG WANG** · enrollment: 44 (estimated)

## Conditions studied

- Locally Advanced Non-Small Cell Lung Cancer
- Thoracic Radiotherapy
- Safety

## Interventions

- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT07037680
- **Lead sponsor:** JIANYANG WANG
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-01
- **Primary completion:** 2026-01-01
- **Final completion:** 2026-06-30
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2025-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07037680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07037680, "Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07037680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*